Bormioli Pharma, an international leader in the production of pharmaceutical packaging and medical devices, launches two new contests in collaboration with the open innovation platform Desall.com.
After the success of the past two editions, Bormioli Pharma is renewing its partnership with Desall.com to gather new stimuli and innovation ideas, ensuring an effective response to emerging trends and the real needs of patients worldwide. Once again this year, talent from the international innovation community is being called upon to present new ideas and designs for pharmaceutical packaging with two particular focuses:
- Augmented reality solutions capable of innovating drug delivery methodology;
- Biometric recognition solutions to revolutionise current child-resistant closure systems;
These two areas were identified during an idea generation process conducted in recent months by Bormioli Pharma in collaboration with the CDI (Collegè des Ingénieurs) Italy and involving a multi-department team from the company. In particular, the process looked at data and insights from research conducted to investigate patients’ medication habits and needs, and which revealed areas for improvement with regard to self-medication in the home.
“We have always supported an open approach to innovation, capable of transforming the insights we receive from end users into concrete solutions, thanks to the involvement of an ecosystem of innovators and external partners,” explains Andrea Lodetti, CEO at Bormioli Pharma. “Given the success of the past editions, we have decided to repeat the collaboration with Desall.com, giving new energy to a path that has already re ceived very positive feedback in the market”.
“It was with great pleasure and enthusiasm that we accepted Bormioli Pharma’s invitation to collaborate again, reaffirming our interest in an industry as relevant as pharmaceutical packaging, which plays a key role in bringing real innovation to people’s daily lives,” says Davide Scomparin, CEO at Desall.com.
The winners of the two competitions will be rewarded with a monetary prize and will have the opportunity to contribute to the development of their project, which may then become a prototype and, if there is interest from pharmaceutical partners, a marketable product on an industrial scale.
These two new call4ideas join the previous ones of 2021 and 2022, which saw the submission of 73 and 109 projects respectively, from dozens of countries from all over the world.
